Literature DB >> 8678616

Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma?

T Harada1, K Matsuo, T Inoue, S Tamesue, T Inoue, H Nakamura.   

Abstract

OBJECTIVE: The value of preoperative transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC) has not been duly appreciated. The authors assessed the advantages and disadvantages of preoperative TACE by reviewing their experience with the procedure.
METHODS: A total of 140 patients who underwent hepatectomy for HCC were entered into the study (105 received preoperative TACE and 35 did not). The authors investigated the reduction of tumor size and the complications after TACE, as well as the relationship between the interval from TACE to resection and the occurrence of complications. They compared postoperative morbidity and mortality between the TACE and non-TACE groups. They also compared survival and disease-free survival between the two groups, as well as between subgroups, defined by the extent of tumor necrosis achieved with TACE.
RESULTS: A distinct reduction of tumor size was observed in approximately half of the TACE group. However, there were 68 appreciable complications of TACE in 56 patients (53.3%), and the interval between TACE and resection was significantly prolonged in the patients with complications. The postoperative morbidity and mortality rates of the TACE group were not different from those of the non-TACE group. Preoperative TACE did not improve the survival or disease-free survival of the whole patient group after hepatectomy. In addition, the survival and disease-free survival rates of the three TACE subgroups were not different from those of the non-TACE group.
CONCLUSIONS: Preoperative TACE should only be performed to reduce tumor bulk in patients with HCC with borderline resectability. In such patients, increased tumor resectability appears to improve the survival rate. Preoperative TACE does not promote tumor recurrence.

Entities:  

Mesh:

Year:  1996        PMID: 8678616      PMCID: PMC1235240          DOI: 10.1097/00000658-199607000-00002

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  16 in total

1.  Postresection recurrence of hepatocellular carcinoma treated by arterial embolization: analysis of prognostic factors.

Authors:  K Takayasu; F Wakao; N Moriyama; Y Muramatsu; S Yamazaki; T Kosuge; T Takayama; S Okada; N Okazaki; M Makuuchi
Journal:  Hepatology       Date:  1992-10       Impact factor: 17.425

2.  Transcatheter arterial embolization in unresectable hepatocellular carcinoma.

Authors:  R Yamada; K Kishi; T Sonomura; M Tsuda; S Nomura; M Satoh
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

Review 3.  Surgery and portal hypertension.

Authors:  C G Child; J G Turcotte
Journal:  Major Probl Clin Surg       Date:  1964

4.  Percutaneous ethanol injection therapy of hepatoma.

Authors:  T Livraghi; C Vettori
Journal:  Cardiovasc Intervent Radiol       Date:  1990 Jun-Jul       Impact factor: 2.740

5.  Lack of intrahepatic recurrence of hepatocellular carcinoma by temporary portal venous embolization with starch microspheres.

Authors:  T Matsumata; T Kanematsu; K Takenaka; K Sugimachi
Journal:  Surgery       Date:  1989-02       Impact factor: 3.982

6.  Transcatheter chemo-embolization effective for treating hepatocellular carcinoma. A histopathologic study.

Authors:  M Sakurai; J Okamura; C Kuroda
Journal:  Cancer       Date:  1984-08-01       Impact factor: 6.860

7.  Experience with 225 hepatic resections for hepatocellular carcinoma over a 4-year period.

Authors:  K Ozawa; T Takayasu; K Kumada; Y Yamaoka; K Tanaka; N Kobayashi; T Inamoto; Y Shimahara; K Mori; K Honda
Journal:  Am J Surg       Date:  1991-06       Impact factor: 2.565

8.  Hepatic resection is not enough for hepatocellular carcinoma. A follow-up study of 92 patients.

Authors:  T Harada; T Shigemura; S Kodama; T Higuchi; S Ikeda; M Okazaki
Journal:  J Clin Gastroenterol       Date:  1992-04       Impact factor: 3.062

9.  Hepatocellular carcinoma: a multivariate analysis of prognostic features in patients treated with hepatic arterial embolization.

Authors:  H Shijo; M Okazaki; H Higashihara; F Koganemaru; M Okumura
Journal:  Am J Gastroenterol       Date:  1992-09       Impact factor: 10.864

10.  Do the tumor cells of hepatocellular carcinomas dislodge into the portal venous stream during hepatic resection?

Authors:  N Yamanaka; E Okamoto; S Fujihara; T Kato; J Fujimoto; T Oriyama; M Mitsunobu; A Toyosaka; K Uematsu; K Yamamoto
Journal:  Cancer       Date:  1992-11-01       Impact factor: 6.860

View more
  31 in total

1.  A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma.

Authors:  Masaki Kaibori; Noboru Tanigawa; Shuji Kariya; Hiroki Ikeda; Yoshitsugu Nakahashi; Junko Hirohara; Chizu Koreeda; Toshihito Seki; Satoshi Sawada; Kazuichi Okazaki; A-Hon Kwon
Journal:  Dig Dis Sci       Date:  2012-01-24       Impact factor: 3.199

2.  Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma.

Authors:  Weiguang Xu; Jung-Hee Kwon; Young Ho Moon; Young Bae Kim; Yun Suk Yu; Namgyu Lee; Kwan Yong Choi; Yun Soo Kim; Yong Keun Park; Bong Wan Kim; Hee Jung Wang
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-23       Impact factor: 4.553

3.  Use of the triaxial microcatheter method in super-selective transcatheter arterial chemoembolisation for hepatocellular carcinoma.

Authors:  M Shimohira; H Ogino; T Kawai; A Kushita; M Watanabe; T Kawaguchi; K Kurono; Y Shibamoto
Journal:  Br J Radiol       Date:  2011-02       Impact factor: 3.039

4.  Chemoembolization for hepatocellular carcinoma. What, when, and for whom?

Authors:  T Lehnert; C Herfarth
Journal:  Ann Surg       Date:  1996-07       Impact factor: 12.969

5.  Complete hepatocellular carcinoma necrosis following sequential porto-arterial embolization.

Authors:  Stéphane Zalinski; Olivier Scatton; Bruto Randone; Olivier Vignaux; Bertrand Dousset
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

6.  Efficacy of preoperative radiotherapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma.

Authors:  Toshiya Kamiyama; Kazuaki Nakanishi; Hideki Yokoo; Munenori Tahara; Takahito Nakagawa; Hirofumi Kamachi; Hiroshi Taguchi; Hiroki Shirato; Michiaki Matsushita; Satoru Todo
Journal:  Int J Clin Oncol       Date:  2007-10-22       Impact factor: 3.402

7.  Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: relation between postoperative course and the pattern of tumor recurrence.

Authors:  Hiroyuki Sugo; Shunji Futagawa; Tomoe Beppu; Masaki Fukasawa; Kuniaki Kojima
Journal:  World J Surg       Date:  2003-11-05       Impact factor: 3.352

8.  Preresection transarterial chemoembolization for hepatocellular carcinoma: an experience with 23 patients.

Authors:  Mahesh Goel; Vinay Gaikwad; Tejas Dharia; Suyash Kulkarni; Nitin Shetty; Shailesh V Shrikhande
Journal:  Indian J Gastroenterol       Date:  2014-07-19

9.  Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (≥10 cm) hepatocellular carcinomas: A clinical study.

Authors:  Nan Bao Zhong; Guang Ming Lv; Zhong Hua Chen
Journal:  Mol Clin Oncol       Date:  2014-06-06

10.  Real-time quantification of AFP mRNA to assess hematogenous dissemination after transarterial chemoembolization of hepatocellular carcinoma.

Authors:  Marine Gross-Goupil; Raphaël Saffroy; Daniel Azoulay; Sophie Precetti; Jean-François Emile; Valérie Delvart; Fréderic Tindilière; Alexis Laurent; Marie-France Bellin; Henri Bismuth; Brigitte Debuire; Antoinette Lemoine
Journal:  Ann Surg       Date:  2003-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.